These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9766344)

  • 1. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
    Herd JA
    Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
    Herd JA
    Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of statins in the management of atherosclerosis.
    Vaughan CJ; Gotto AM; Basson CT
    J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvastatin: a review of its use in lipid disorders.
    Langtry HD; Markham A
    Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
    Callister TQ; Raggi P; Cooil B; Lippolis NJ; Russo DJ
    N Engl J Med; 1998 Dec; 339(27):1972-8. PubMed ID: 9869668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors.
    Rubenfire M; Coletti AT; Mosca L
    Prog Cardiovasc Dis; 1998; 41(2):95-116. PubMed ID: 9790412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
    Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
    Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
    Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation.
    Achenbach S; Ropers D; Pohle K; Leber A; Thilo C; Knez A; Menendez T; Maeffert R; Kusus M; Regenfus M; Bickel A; Haberl R; Steinbeck G; Moshage W; Daniel WG
    Circulation; 2002 Aug; 106(9):1077-82. PubMed ID: 12196332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 16. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent clinical studies of the effects of lipid-modifying therapies.
    Gotto AM; Moon JE
    Am J Cardiol; 2012 Jul; 110(1 Suppl):15A-26A. PubMed ID: 22697388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-Modifying Drugs: Pharmacology and Perspectives.
    Xu RX; Wu YJ
    Adv Exp Med Biol; 2020; 1177():133-148. PubMed ID: 32246446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
    Rackley CE
    Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.